PARP1 and neoplasm: A newly identified PolQ inhibitor Novobiocin resensitized these cancer cells to PARPi in vitro and in vivo by increasing the excessive DSB end resection and nonfunctional RAD51 foci-loading rates in HRD and PARP-inhibitor-resistant tumor cells [121].